Search the Newsreel

Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A

Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …

Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals

Vistagen Therapeutics, Inc. announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder. The study met its safety objective and showed efficacy signals, particularly in patients with very severe social anxiety, which will inform discussions with the FDA …

VistaGen Granted Nasdaq Extension to Regain Bid Compliance

VistaGen Therapeutics has received a 180-day extension from Nasdaq, lasting until February 1, 2027, to meet the $1.00 minimum bid price requirement for its common stock. Failure to comply within this period could lead to delisting. Analysts currently rate VTGN as a Hold with …

Vistagen's second fasedienol dose showed no new safety findings

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder, showing repeat dosing was safe and well-tolerated with no new safety findings. While overall statistical significance was not met for primary efficacy endpoints, nominally significant …

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder. The study showed favorable safety and tolerability, with efficacy signals observed across primary and secondary endpoints, particularly in patients with very severe …

Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension

Vistagen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq, until February 1, 2027, to regain compliance with the $1.00 per share minimum bid price requirement. The company's common stock listing remains effective, and Vistagen intends to cure the deficiency within this period …

Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Vistagen Therapeutics (VTGN) announced it received an extension from Nasdaq until February 1, 2027, to meet the $1.00 minimum bid price requirement. The company's listing remains active during this period, but failure to comply could lead to delisting. This information is based on an …

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG

Robbins LLP is reminding investors that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on behalf of stockholders who purchased shares between April 1, 2024, and December 16, 2025. The lawsuit alleges that Vistagen misled investors regarding the viability …

Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Vistagen Therapeutics Inc is projected to report a loss of 36 cents per share, according to an earnings preview. The article indicates that this information is sourced from Refinitiv. Readers are prompted to access the full article through a paid subscription on TradingView.

SRX Global acquires stake in Vistagen Therapeutics

SRX Global has acquired a minority equity stake in Vistagen Therapeutics, a Nasdaq-listed biotech company. The investment targets Vistagen's late-stage neuroscience pipeline, specifically its intranasal "pherine" product candidates. SRX Global believes Vistagen shares are undervalued and plans to engage with management and the board …

Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for VistaGen Therapeutics Inc. as of July 31. Form 4s disclose transactions made by company insiders and are important for investors to track. The article is very brief, serving primarily as an announcement of the filing …

Press Release: Vistagen Appoints Douglas J. Williamson to Its Board of Directors

Vistagen Therapeutics, Inc. has announced the appointment of Douglas J. Williamson, M.D. to its Board of Directors. Dr. Williamson brings extensive experience in psychiatric drug development and will also serve on the Nominating & Corporate Governance Committee. This appointment expands Vistagen's Board to eight …

Vistagen Therapeutics (NASDAQ: VTGN) sets 2026 virtual meeting, director slate and pay vote

Vistagen Therapeutics (NASDAQ: VTGN) has announced its 2026 annual virtual meeting for September 10, 2026. Stockholders will vote on the election of four directors, a non-binding advisory vote on Named Executive Officer compensation, and the ratification of KPMG LLP as the independent auditor. The …

Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Vistagen Therapeutics Inc (VTGN), ranking it 315 out of 385 in the Biotechnology & Medical Research industry with a score of 1.25. It highlights the company's beta value of 0.31, indicating lower volatility compared to the S&P …

Vistagen Therapeutics (Nasdaq: VTGN) names Douglas J. Williamson to board

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) has appointed Douglas J. Williamson, M.D. to its Board of Directors, effective July 29, 2026. Dr. Williamson, who has nearly three decades of experience in neuroscience drug development, received stock options and will be compensated under the company's Director …

VistaGen files Form 3 as director Douglas J. Williamson reports no beneficial ownership

VistaGen Therapeutics director Douglas J. Williamson has filed an initial Form 3, indicating no beneficial ownership. This filing was made on July 31, 2026, and the information was originally published via EDGAR by VistaGen Therapeutics Inc. The news brief is an AI-generated content for …

Vistagen adds board director with nearly three decades in neuroscience drug development

Vistagen (Nasdaq: VTGN) has appointed Douglas J. Williamson, MD, to its Board of Directors, leveraging his nearly three decades of experience in neuroscience drug development, clinical research, and regulatory strategy. Dr. Williamson's background includes leadership roles at several biopharmaceutical companies and contributions to the …

Vistagen Therapeutics Q2 2026 Earnings: EPS Miss Alters Sentiment as Stock Rises - Annual Earnings Summary

Vistagen Therapeutics Q2 2026 Earnings: EPS Miss Alters Sentiment as Stock Rises - Earnings Quality Score

Vistagen Therapeutics Inc (VTGN) Institutional Confidence

Vistagen Therapeutics Inc (VTGN) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 37.96%, a decrease of 34.37% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.74% …

Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Vistagen Therapeutics Inc (VTGN), noting that relevant data regarding business segments and regional revenue contributions have not been disclosed by the company. It briefly shows the stock price, market cap, and the current trading status for VTGN, …

VTGN|Vistagen Therapeutics Inc|Price:0.226|Chg%:+0.000

Vistagen Therapeutics Inc. (VTGN) is currently trading at $0.226, showing a slight increase of 0.18%. The company, a late clinical-stage biopharmaceutical firm, is focused on developing intranasal pherines for neurological conditions. While VTGN exhibits strong fundamentals like revenue and profit growth, and high institutional …

VTGN Stock News Today | Earnings, Events & Price Alerts

This article provides news and event updates for Vistagen Therapeutics (VTGN). Recent news indicates that Vistagen's PALISADE-4 trial for an anxiety drug failed to meet its primary endpoint, leading to a significant stock drop. However, the company also reported positive preliminary data from its …